论文部分内容阅读
目的:探讨丁苯酞对急性进展性脑梗死患者血同型半胱氨酸(Hcy)、C反应蛋白(CRP)及神经功能的影响。方法:122例急性进展性脑梗死患者随机分为观察组(n=60)和对照组(n=62)。对照组采用常规对症治疗,观察组在对照组基础上加用丁苯酞治疗。两组疗程均为2周。比较两组临床总有效率,以及两组患者治疗前后血Hcy、血浆CRP水平及神经功能缺损评分变化。结果:观察组总有效率为81.67%,显著高于对照组的64.52%(P<0.05)。治疗后两组血Hcy、CRP均较治疗前显著降低(P<0.05),且观察组显著低于对照组(P<0.05)。两组神经功能缺损评分治疗后均较前显著降低(P<0.05),且观察组显著低于同期对照组(P<0.05)。两组治疗期间均未发生明显不良反应。结论:丁苯酞对急性进展性脑梗死患者效果明显,可明显降低血Hcy、CRP水平,减少神经功能缺损评分,改善神经功能,且无明显不良反应。
Objective: To investigate the effect of butylphthalide on blood homocysteine (Hcy), C-reactive protein (CRP) and neurological function in patients with acute progressive cerebral infarction. Methods: A total of 122 patients with acute progressive cerebral infarction were randomly divided into observation group (n = 60) and control group (n = 62). The control group was treated with conventional symptomatic treatment. The observation group was treated with butylphthalide on the basis of the control group. Two groups of treatment are 2 weeks. The total effective rate of the two groups was compared, and the changes of blood Hcy, plasma CRP level and neurological deficit scores before and after treatment were compared between the two groups. Results: The total effective rate in observation group was 81.67%, which was significantly higher than that in control group (64.52%, P <0.05). After treatment, the levels of Hcy and CRP in both groups were significantly lower than those before treatment (P <0.05), and the observation group was significantly lower than the control group (P <0.05). The score of neurological deficit in both groups was significantly lower than that before treatment (P <0.05), and the observation group was significantly lower than the control group (P <0.05). No significant adverse reactions occurred during the two groups. CONCLUSION: Butylphthalide is effective in patients with acute progressive cerebral infarction. It can significantly reduce blood levels of Hcy and CRP, decrease neurological deficit scores, improve neurological function, and have no obvious adverse reactions.